Safety of Lecanemab After 6‐Month Treatment in the DIAN‐TU‐001 Trial
Lecanemab was generally well-tolerated. The most common adverse events of lecanemab in the DIAD population were ARIA-H, headache, ARIA-E, and infusion-related reactions. DIAD population may have a higher rate of cerebral amyloid angiopathy with ARIA rates between heterozygotes and homozygotes in sporadic AD.
Authors
- Erica Andreozzi
- Eric McDade (ORCID: https://orcid.org/0000-0002-6764-3866)
- Jorge J. Llibre‐Guerra (ORCID: https://orcid.org/0000-0002-2137-7750)
- Guoqiao Wang
- David B. Clifford
- Randall J. Bateman
- Larisa Reyderman
- Jin Zhou
- David Li
- Lon S. S Schneider
Institutions
- Washington University in St. Louis (US)
- Keck Hospital of USC (US)
- Eisai (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_105304
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00